Presage Biosciences Presents Data Demonstrating Tumor Growth Inhibition By Voruciclib And Proteasome Inhibitors Superior To Single Agents In Model Of Triple Negative Breast Cancer

SEATTLE--(BUSINESS WIRE)--Presage Biosciences, an oncology company that is developing a novel drug development platform to assess drug combinations directly in patient tumors, will present preclinical data showing that the company’s clinical-stage oral CDK inhibitor, voruciclib, in combination with proteasome inhibitors, demonstrated superior tumor growth inhibition in xenografts than the single agents separately in a model of triple negative breast cancer (TNBC), a disease which has proven challenging to treat with standard chemotherapy options. The data are being presented today at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans.